Peremiquel-Trillas, Paula , Paytubi, Sonia , Pelegrina, Beatriz , Frias-Gomez, Jon , CARMONA PESTAÑA, ÁLVARO, Manuel Martinez, Jose , de Francisco, Javier , Benavente, Yolanda , Barahona, Marc , Brianso, Ferran , Canet-Hermida, Julia , Cano, Victor , Vidal, August , Zanca, Alba , Baixeras, Nuria , Rodriguez, Axel , Fernandez-Gonzalez, Sergi , Duenas, Nuria , Cardenas, Laura , Aytes, Alvaro , Bianchi, Ilaria , Angel Pavon, Miquel , Reventos, Jaume , Capella, Gabriel , Gomez, David , Diaz, Mireia , Ponce, Jordi , Brunet, Joan , Matias-Guiu, Xavier , Xavier Bosch, Francesc , de Sanjose, Silvia , Alemany, Laia , Pineda, Marta , Marin, Fatima , Costas, Laura
Si
J. Pers. Med.
Article
Científica
0.665
01/07/2022
000833684700001
Screenwide is a case-control study (2017-2021) including women with incident endometrial and ovarian cancers (EC and OC), BRCA1/2 and MMR pathogenic variant carriers, and age-matched controls from three centers in Spain. Participants completed a personal interview on their sociodemographic factors, occupational exposure, medication, lifestyle, and medical history. We collected biological specimens, including blood samples, self-collected vaginal specimens, cervical pap-brush samples, uterine specimens, and, when available, tumor samples. The planned analyses included evaluation of the potential risk factors for EC/OC; evaluation of molecular biomarkers in minimally invasive samples; evaluation of the cost-effectiveness of molecular tests; and the generation of predictive scores to integrate different epidemiologic, clinical, and molecular factors. Overall, 182 EC, 69 OC, 98 BRCA pathogenic variant carriers, 104 MMR pathogenic variant carriers, and 385 controls were enrolled. The overall participation rate was 85.7%. The pilot study using 61 samples from nine EC cases and four controls showed that genetic variants at the variant allele fraction > 5% found in tumors (n = 61 variants across the nine tumors) were detected in paired endometrial aspirates, clinician-collected cervical samples, and vaginal self-samples with detection rates of 90% (55/61), 79% (48/61), and 72% (44/61) by duplex sequencing, respectively. Among the controls, only one somatic mutation was detected in a cervical sample. We enrolled more than 800 women to evaluate new early detection strategies. The preliminary data suggest that our methodological approach could be useful for the early detection of gynecological cancers.
endometrial cancer; ovarian cancer; early detection; pap smears; self-sampling; genomic